Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biogen (BIIB)
NASDAQ:BIIB
BIIB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$128.51 - $238.00
Previous CloseN/A
Volume268.56K
Average Volume (3M)1.46M
Market Cap
$19.99B
Enterprise Value$33.27B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)12.2
Beta0.72
Next Earnings
Apr 23, 2025EPS Estimate
3.59Last Dividend Ex-Date
Feb 02, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)11.18
Shares Outstanding146,374,940
10 Day Avg. Volume1,833,576
30 Day Avg. Volume1,461,290
Standard Deviation0.09
R-Squared0.00231
Alpha-0.00558
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.07
Price to Cash Flow (P/CF)6.60
P/FCF Ratio6.10
Enterprise Value/Market Cap1.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.44
Enterprise Value/Ebitda14.50
Forecast
1Y Price Target
$191.86Price Target Upside39.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering25
---
Bulls Say, Bears Say
Bulls Say
CollaborationBiogen announced a collaboration with Stoke Therapeutics for the development of a treatment for Dravet syndrome, which aligns with their expertise in neuro, immunology, and rare diseases.
Product GrowthLeqembi continues its positive trajectory especially in the USA, supporting the real-world data from the academic centers.
Bears Say
Revenue GuidanceThe stock is down 4% as the midpoint of the 2025 EPS guidance is notably below consensus.
---
Ownership Overview
0.17% Insiders
33.77% Mutual Funds
22.21% Other Institutional Investors
11.11% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BIIB FAQ
What was Biogen’s price range in the past 12 months?
Biogen lowest stock price was $128.51 and its highest was $238.00 in the past 12 months.
What is Biogen’s market cap?
Biogen’s market cap is $19.99B.
When is Biogen’s upcoming earnings report date?
Biogen’s upcoming earnings report date is Apr 23, 2025 which is in 61 days.
How were Biogen’s earnings last quarter?
Biogen released its earnings results on Feb 12, 2025. The company reported $3.44 earnings per share for the quarter, beating the consensus estimate of $3.331 by $0.109.
Is Biogen overvalued?
According to Wall Street analysts Biogen’s price is currently Undervalued.
Does Biogen pay dividends?
Biogen pays a Notavailable dividend of $22.225 which represents an annual dividend yield of N/A. See more information on Biogen dividends here
What is Biogen’s EPS estimate?
Biogen’s EPS estimate is 3.59.
How many shares outstanding does Biogen have?
Biogen has 146,374,940 shares outstanding.
What happened to Biogen’s price movement after its last earnings report?
Biogen reported an EPS of $3.44 in its last earnings report, beating expectations of $3.331. Following the earnings report the stock price went down -4.276%.
Which hedge fund is a major shareholder of Biogen?
Currently, no hedge funds are holding shares in BIIB
---
Biogen Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$191.86 (39.96% Upside)
$191.86 (39.96% Upside)
Blogger Sentiment
Bullish
BIIB Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 114.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $17.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 3.9%
Last 30 Days ▲ 3.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.46%
12-Months-Change
Fundamentals
Return on Equity
10.36%
Trailing 12-Months
Asset Growth
4.49%
Trailing 12-Months
Company Description
Biogen
Incorporated in 1978, Massachusetts-based Biogen, Inc. is a biopharmaceutical company, which discovers, develops, and delivers therapies for the treatment of neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis.
---
BIIB Company Deck
---
BIIB Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Biogen's earnings call highlighted successful new product launches and operational efficiency, offsetting declines in its multiple sclerosis franchise. However, challenges persist in identifying patients for SKYCLARYS and pressure on MS revenues is expected to continue.Read More>---
BIIB Revenue Breakdown
74.55% Product revenue
18.09% Revenue from anti-CD20 therapeutic programs
6.74% Contract manufacturing, royalty and other revenue
0.62% Alzheimer's collaboration revenue
---
BIIB Stock 12 Month Forecast
Average Price Target
$191.86
▲(39.96% Upside)
Technical Analysis
Best Analysts Covering BIIB
1 Year
1 Year Success Rate
11/39 ratings generated profit
1 Year Average Return
-7.75%
reiterated a buy rating 9 days ago
Copying Marc Goodman's trades and holding each position for 1 Year would result in 28.21% of your transactions generating a profit, with an average return of -7.75% per trade.
---